Get the Stockscreener App
1.225
0.83%
0.015
Alx Oncology Holdings Inc stock is traded at $1.225, with a volume of 156.49K.
It is up +0.83% in the last 24 hours and down -18.67% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$1.21
Open:
$1.22
24h Volume:
156.49K
Relative Volume:
0.24
Market Cap:
$64.61M
Revenue:
-
Net Income/Loss:
$-160.81M
P/E Ratio:
-0.3828
EPS:
-3.2
Net Cash Flow:
$-131.64M
1W Performance:
-8.27%
1M Performance:
-18.67%
6M Performance:
-91.04%
1Y Performance:
-86.67%
1-Day Range:
$1.21
$1.25
1-Week Range:
$1.19
$1.35
52-Week Range:
$1.19
$17.82
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| ALXO | 1.225 | 64.61M | 0 | -160.81M | -131.64M | -3.20 |
| VRTX | 447.00 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 746.00 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 589.80 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.91 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 103.73 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
ALX Oncology Highlights Promising Trial Results - MSN
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update - Defense World
ALX Oncology FY2024 EPS Forecast Raised by Cantor Fitzgerald - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Significant Decrease in Short Interest - MarketBeat
Brokers Set Expectations for ALX Oncology FY2024 Earnings - MarketBeat
Former Mirati CMO Alan Sandler joins ALX Oncology - The Pharma Letter
Data-Based Insights About XBP Europe Holdings Inc (XBP) - Stocks Register
New Outlook On Celsius Holdings Inc - Stocks Register
ALX Oncology Strengthens Leadership with Key Appointment - TipRanks
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer - GlobeNewswire
ALX Oncology Appoints Former Mirati & Genentech Exec as Chief Medical Officer | ALXO Stock News - StockTitan
Cantor Fitzgerald Reiterates Overweight Rating for ALX Oncology (NASDAQ:ALXO) - Defense World
ALXO stock touches 52-week low at $1.31 amid market challenges - Investing.com
FMR LLC's Strategic Reduction in ALX Oncology Holdings Inc Shares - GuruFocus.com
ALX Oncology's (ALXO) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Brokers Issue Forecasts for ALX Oncology FY2028 Earnings - MarketBeat
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
ALX Oncology Announces November Investor Conference Participation - GlobeNewswire
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
ALXOALX Oncology Holdings Inc. Latest Stock News & Market Updates - StockTitan
ALX Oncology Announces Results from Phase 1b/2 Trial of - GlobeNewswire
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 - StockTitan
ALXO stock touches 52-week low at $1.42 amid market challenges - Investing.com Australia
ALXO stock touches 52-week low at $1.42 amid market challenges By Investing.com - Investing.com South Africa
SG Americas Securities LLC Has $50,000 Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Down 6.7% in September - MarketBeat
Technical analysis of Alx Oncology Holdings Inc (ALXO) stock chart patterns - US Post News
ALXO Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
Closing Figures: Alx Oncology Holdings Inc (ALXO)’s Negative Finish at 1.44, Down -11.11 - The Dwinnex
SVP, FINANCE AND CAO Pinto Shelly sale 564 shares of Alx Oncology Holdings Inc [ALXO] - Knox Daily
Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc - Yahoo Finance
ALXO stock touches 52-week low at $1.55 amid market challenges By Investing.com - Investing.com South Africa
ALXO stock touches 52-week low at $1.55 amid market challenges - Investing.com
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $12.20 Average PT from Brokerages - MarketBeat
ALX Oncology Holdings Drops To US$1.68, Yet Insiders May Have Sold Too Early - Simply Wall St
American Century Companies Inc. Cuts Stake in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
A company insider recently sold 564 shares of Alx Oncology Holdings Inc [ALXO]. Should You Sale? - Knox Daily
ALX Oncology Chief Medical Officer resigns, search for replacement begins - Investing.com India
Point72 Asset Management L.P. Makes New $1.83 Million Investment in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology CMO Sophia Randolph Announces Resignation - TipRanks
ALX Oncology Chief Medical Officer resigns, search for replacement begins By Investing.com - Investing.com UK
ALX Oncology Holdings Inc. Announces Resignation of Sophia Randolph as Chief Medical Officer, Effective October 11, 2024 - Marketscreener.com
Point72 Asset Management L.P. Acquires New Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - MarketBeat
ALXO stock touches 52-week low at $1.75 amid market challenges By Investing.com - Investing.com South Africa
ALXO stock touches 52-week low at $1.75 amid market challenges - Investing.com
Marshall Wace LLP Has $3.83 Million Stake in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
You might want to take a look at Alx Oncology Holdings Inc (ALXO) now - SETE News
Renaissance Technologies LLC Increases Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
Breast Cancer Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
ALXO’s 2023 Market Dance: Down -87.78% – Time to Invest? - The InvestChronicle
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alx Oncology Holdings Inc Stock (ALXO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Randolph Sophia | CHIEF MEDICAL OFFICER |
Aug 14 '24 |
Sale |
2.58 |
1,365 |
3,522 |
325,711 |
| Pons Jaume | PRESIDENT & CSO |
Aug 14 '24 |
Sale |
2.58 |
1,937 |
4,997 |
591,510 |
| Pons Jaume | PRESIDENT & CSO |
Jul 11 '24 |
Option Exercise |
0.99 |
20,000 |
19,800 |
613,447 |
| Pons Jaume | PRESIDENT & CSO |
Jul 11 '24 |
Sale |
7.90 |
20,000 |
158,076 |
593,447 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 05 '24 |
Sale |
5.50 |
1,823 |
10,025 |
92,113 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 01 '24 |
Sale |
5.82 |
1,373 |
7,989 |
93,936 |
| Randolph Sophia | CHIEF MEDICAL OFFICER |
Jul 01 '24 |
Sale |
5.82 |
3,273 |
19,045 |
327,076 |
| Pons Jaume | PRESIDENT & CSO |
Jul 01 '24 |
Sale |
5.82 |
10,758 |
62,599 |
593,447 |
| GARCIA PETER S | CHIEF FINANCIAL OFFICER |
Jun 13 '24 |
Buy |
8.53 |
12,000 |
102,338 |
122,348 |
| Pons Jaume | PRESIDENT & CSO |
Jun 04 '24 |
Option Exercise |
0.99 |
20,000 |
19,800 |
624,205 |
0.42%
0.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):